A US appeals court has issued a ruling that could severely limit access to mifepristone, a medication approved by the US Food and Drug Administration (FDA) for use in ending pregnancies. The decision, handed down on Friday, temporarily blocks the drug from being dispensed through the mail. This move has been described by abortion rights supporters as the most sweeping threat to access since the Supreme Court overturned Roe v Wade in 2022, a landmark ruling that had previously protected the right to abortion across the United States.
Mifepristone is a crucial component of medication abortion, which accounts for more than half of all abortions in the US. The ability to receive the drug via mail has expanded access, particularly for individuals in rural areas or those facing other barriers to in-person clinic visits. The appeals court's decision, if it stands, would mandate that the drug can only be dispensed in person by a doctor, effectively rolling back recent changes that allowed for its wider distribution.
The legal challenge centres on the FDA's initial approval of mifepristone and subsequent decisions to broaden its availability. Opponents of abortion have argued that the FDA did not adequately assess the drug's safety, a claim that the FDA and numerous medical organisations dispute. This legal battle is unfolding against a backdrop of intense political and social debate surrounding abortion rights in the United States, with various states implementing their own restrictions following the Supreme Court's 2022 decision.
While this ruling is temporary, its implications are significant. It underscores the ongoing legal challenges to abortion access in the US and the potential for federal courts to reshape the landscape of reproductive healthcare. The ultimate outcome of this legal process could have far-reaching consequences for millions of Americans seeking abortion services.